Real-life prognosis of neurological complications of botulinum toxin: A nationwide pharmacovigilance study of adverse drug reactions reported in France between 1994 and 2020
Vincent T. Carpentier(Université de Versailles Saint-Quentin-en-Yvelines), Kévin Bihan(Sorbonne Université), François Montastruc(Centre d’Investigation Clinique 1436), Jonathan Lévy(Centre National de la Recherche Scientifique), Nicolas Weiss(Sorbonne Université), Bénédicte Lebrun‐Vignes(Sorbonne Université), Djamel Bensmaïl(Inserm), François Genêt, Louise‐Laure Mariani(Centre National de la Recherche Scientifique), Charles Joussain(CHU Dijon Bourgogne), P. Denys(Inserm), Joe‐Elie Salem(Inserm), Julien Mahé(Centre Hospitalier Universitaire de Nantes)
Cited by 3
Related Papers
Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study
|Intensive Care Medicine|2021|420
Trial of Lixisenatide in Early Parkinson’s Disease
|New England Journal of Medicine|2024|302
Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology
|Nature Communications|2020|275
Intestinal inhibition of Atg7 prevents tumour initiation through a microbiome-influenced immune response and suppresses tumour growth
|Nature Cell Biology|2015|183
Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin
|Journal of Thrombosis and Haemostasis|2016|140